Guidelines are mainly based on evidence of well-designed randomized controlled trials
(RCTs), but there are limitations to the transferability of conclusions of RCTs to usual care …

We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …

Rationale: There is uncertainty on the use of using triple therapy (inhaled
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document for the
treatment of chronic obstructive pulmonary disease (COPD) suggests that, after …

Introduction Treatment of chronic obstructive pulmonary disease (COPD) is evolving
specially with triple inhaler therapy. Objectives To perform a meta‐analysis to ascertain the …

Background: Chronic obstructive pulmonary disease (COPD) guidelines recommend both
long-acting and dual bronchodilator therapy. It is unclear if there are differences in efficacy …

Objective To compare the rate of moderate to severe exacerbations between triple therapy
and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease …

Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …

Background This study aims to compare the effects of single inhaler triple therapy comprised
of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting …

Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic
obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared …